Amprenavir is a protease inhibitor used to treat HIV infection. It was approved by
the Food and Drug Administration on April 15, 1999, for twice-a-day dosing ...
Accession Number, DB00701 (APRD00605). Type, Small Molecule. Groups,
Approved. Description, Amprenavir is a protease inhibitor used to treat HIV
Easy to read patient leaflet for amprenavir. Includes indications, proper use,
special instructions, precautions, and possible side effects.
Learn about Agenerase Capsules (Amprenavir Capsules) may treat, uses,
dosage, side effects, drug interactions, warnings, patient labeling, reviews, and ...
Amprenavir is a white to cream-colored solid with a solubility of approximately
0.04 mg/mL in water at 25°C. AGENERASE Capsules are available for oral ...
Jan 25, 2001 ... Approval. Amprenavir was approved by the U.S. Food and Drug Administration (
FDA) in 1999 for use in adults and children with HIV infection.
Agenerase (amprenavir): For the treatment of HIV-1 infection.. New approved
drug details including side effects, uses and general information.
AGENERASE (amprenavir) in combination with other antiretroviral agents is
indicated for ... contains 15 mg of amprenavir in solution and the inactive
Amprenavir is an antiretroviral drug used to treat HIV/AIDS. It is branded under
the tradename Agenerase. Glaxo began marketing Agenerase in April 1999.
crystal structure of inhibitor amprenavir in complex with a multi-drug resistant
variant of HIV-1 protease (L63P/V82T/I84V). DOI: 10.2210/pdb1t7j/pdb.